Company intelligence / Profile preview
Helix BioPharma
Vancouver, British Columbia, Canadahelixbiopharma.com ↗
- Ownership
- Private
- Employees
- ~7
- Development stage
- Other
01
Overview
Helix BioPharma develops novel oncology therapeutics using a proprietary antibody-enzyme conjugate platform targeting the tumor microenvironment. Its lead candidate L-DOS47 has completed Phase Ib studies in non-small cell lung cancer and the company recently expanded its pipeline with two preclinical oral agents through acquisition. The company’s programs focus on hard-to-treat solid tumors and post-transplant leukemia relapse, with ongoing collaborations to explore combination therapies and next-generation ADCs.
- Therapeutic areas
- Oncology
- Modalities
- Antibody-enzyme conjugate (AEC)Small moleculeAntibody-drug conjugate (ADC)Prodrug
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Moffitt Cancer CenterUniversity Hospital Tuebingen
Beyond the preview
Go deeper on Helix BioPharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Helix BioPharma.